Table of Contents
Leukemia Research and Treatment
Volume 2015, Article ID 982395, 12 pages
Research Article

Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis

1Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT-University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, 6060 Hall in Tirol, Austria
2Area Health Technology Assessment, ONCOTYROL-Center for Personalized Cancer Medicine, Karl-Kapferer-Straße 5, 6020 Innsbruck, Austria
3Department of Pharmacotherapy, University of Utah, 30 South 2000, Salt Lake City, UT 84112, USA
4Huntsman Cancer Institute, University of Utah Hospitals & Clinics, 2000 Circle of Hope, Salt Lake City, UT 84112, USA
5Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98104, USA
6Program in Personalized Health, University of Utah, 15 North 2030 East, Room 2110, Salt Lake City, UT 84112, USA
7Center for Health Decision Science, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, 718 Huntington Avenue, Boston, MA 02215, USA
8Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 101 Merrimac Street, Boston, MA 02114, USA

Received 25 August 2015; Revised 5 November 2015; Accepted 11 November 2015

Academic Editor: Mario Tiribelli

Copyright © 2015 Ursula Rochau et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [4 citations]

The following is the list of published articles that have cited the current article.

  • Nanxin Li, Xi Yang, Liangyi Fan, Todor Totev, Annie Guerin, Lei Chen, Subrata Bhattacharyya, and George Joseph, “Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data,” Journal of Medical Economics, pp. 1–9, 2016. View at Publisher · View at Google Scholar
  • Koung Jin Suh, Ji Yun Lee, Dong-Yeop Shin, Youngil Koh, Soo-Mee Bang, Sung-Soo Yoon, Seonyang Park, Inho Kim, and Jeong-Ok Lee, “Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.,” International journal of hematology, vol. 106, no. 2, pp. 229–239, 2017. View at Publisher · View at Google Scholar
  • Na Li, Bin Zheng, Hong-Fu Cai, Jing Yang, Xiao-Feng Luo, Li-Zhu Weng, Feng-Mei Zhan, and Mao-Bai Liu, “Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China,” Clinical Drug Investigation, 2017. View at Publisher · View at Google Scholar
  • Jie Fu, Yuchen Liu, Houwen Lin, and Bin Wu, “Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review,” Clinical Drug Investigation, 2018. View at Publisher · View at Google Scholar